BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29605274)

  • 1. Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice.
    Shiromizu S; Kusunose N; Matsunaga N; Koyanagi S; Ohdo S
    J Pharmacol Sci; 2018 Apr; 136(4):228-233. PubMed ID: 29605274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
    Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
    Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic tumor sensitivity to plasma L-asparagine starvation.
    Dufour E; Gay F; Aguera K; Scoazec JY; Horand F; Lorenzi PL; Godfrin Y
    Pancreas; 2012 Aug; 41(6):940-8. PubMed ID: 22513289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
    Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
    Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
    Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.
    Gutierrez JA; Pan YX; Koroniak L; Hiratake J; Kilberg MS; Richards NG
    Chem Biol; 2006 Dec; 13(12):1339-47. PubMed ID: 17185229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.
    Asselin B; Rizzari C
    Leuk Lymphoma; 2015; 56(8):2273-80. PubMed ID: 25586605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
    Avramis VI; Panosyan EH
    Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
    Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
    Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
    Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
    Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
    Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of Halomonas elongata L-asparaginase, a promising chemotherapeutic agent.
    Ghasemi A; Asad S; Kabiri M; Dabirmanesh B
    Appl Microbiol Biotechnol; 2017 Oct; 101(19):7227-7238. PubMed ID: 28801829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
    Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
    J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
    Earl M
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.